Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 576 adults across three groups: 191 received a placebo (dummy treatment), 191 received mepolizumab given into a vein (75 mg IV), and 194 received mepolizumab given by injection under the skin (100 mg SC). The trial ran for 32 weeks and was primarily measuring how often participants had serious asthma flare-ups — defined as episodes bad enough to need steroid medicines, a hospital stay, or an emergency department visit. The reported data shows that for the main outcome, the placebo group had a reported rate of 1.74 serious flare-ups per year, compared to 0.93 per year in the IV mepolizumab group and 0.83 per year in the under-the-skin mepolizumab group. For flare-ups that led to a hospital stay or emergency department visit, the reported rates were 0.20 (placebo), 0.14 (IV), and 0.08 (under-the-skin) per year. For flare-ups requiring hospitalisation alone, the reported figures were 0.10, 0.06, and 0.03 per year respectively. The reported data also shows that lung function (measured as the amount of air expelled in one second) changed from the starting point by an average of 86 millilitres in the placebo group, 186 mL in the IV group, and 183 mL in the under-the-skin group. Finally, a quality-of-life questionnaire (scored 0–100, where higher scores mean greater impact on daily life) showed average score changes of −9.0 (placebo), −15.4 (IV), and −16.0 (under-the-skin) from the start of the trial. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37131185) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Asthma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are able to read, understand, and sign a consent form before the study begins
- You are at least 12 years old and weigh at least 45 kg (about 99 lbs)
- You have been regularly taking high-dose asthma preventer inhalers (steroid-based) for the past 12 months, with or without steroid tablets
- You have been taking at least one other asthma controller medication for 3 or more months, or you tried one in the past 12 months and it did not work well enough
- You have been diagnosed with, or are very likely to have, a type of asthma linked to high levels of a certain white blood cell called eosinophils
- Your lung function test results fall below a certain level (confirm with trial site for exact numbers based on your age)
- You have had two or more serious asthma attacks in the past that needed steroid treatment
- You are male, or a female who either cannot become pregnant or is willing to use reliable contraception throughout the study
- If you are based in France, you must be part of the French social security system
Who may not be able to join:
- You currently smoke, or you are a former smoker who smoked heavily for 10 or more years
- You have a significant lung condition other than asthma
- You currently have cancer, or have had cancer within the past 12 months
- You have unstable liver disease, cirrhosis, or known problems with your bile ducts
- You have a serious or unstable heart or cardiovascular condition
- You have another significant ongoing health condition that is not well controlled with standard treatment
- You have another medical condition involving high eosinophil levels (a type of white blood cell)
- Your heart's electrical activity (measured by an ECG) shows certain abnormal readings (confirm with trial site)
- You have a history of alcohol or drug misuse
- You have a known problem with your immune system
- You have received a specific asthma injection treatment called omalizumab (Xolair) within about 4 months before the study, or certain other similar biological treatments recently
- You have taken part in a study involving an experimental drug within the past 30 days (or longer, depending on the drug)
- You have an allergy or intolerance to antibody-based or biological treatments
- You are currently pregnant or breastfeeding
- You have a known history of not following prescribed medication routines or medical advice
- You have previously taken part in a study involving the drug mepolizumab and actually received it (including a dummy/placebo version)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: GSK Clinical Trials, GlaxoSmithKline
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Clinically Significant Exacerbations of Asthma Per Year
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.